HIV and Drug-Resistant Subtypes

Overview

Journal Microorganisms

Specialty Microbiology

Date 2023 Jan 21

PMID 36677513

Authors

Bianca Maria Nastri

Pasquale Pagliano

Carla Zannella

Veronica Folliero

Alfonso Masullo

Luca Rinaldi

Massimiliano Galdiero

Gianluigi Franci

Affiliations

Soon will be listed here.

Abstract

Acquired Immunodeficiency Syndrome (AIDS) is a human viral infectious disease caused by the positive-sense single-stranded (ss) RNA Human Immunodeficiency Virus (HIV) (Retroviridae family, Ortervirales order). HIV-1 can be distinguished into various worldwide spread groups and subtypes. HIV-2 also causes human immunodeficiency, which develops slowly and tends to be less aggressive. HIV-2 only partially homologates to HIV-1 despite the similar derivation. Antiretroviral therapy (ART) is the treatment approved to control HIV infection, based on multiple antiretroviral drugs that belong to different classes: (i) NNRTIs, (ii) NRTIs, (iii) PIs, (iv) INSTIs, and (v) entry inhibitors. These drugs, acting on different stages of the HIV life cycle, decrease the patient's total burden of HIV, maintain the function of the immune system, and prevent opportunistic infections. The appearance of several strains resistant to these drugs, however, represents a problem today that needs to be addressed as best as we can. New outbreaks of strains show a widespread geographic distribution and a highly variable mortality rate, even affecting treated patients significantly. Therefore, novel treatment approaches should be explored. The present review discusses updated information on HIV-1- and HIV-2-resistant strains, including details on different mutations responsible for drug resistance.

Citing Articles

Exploratory algorithms to devise multi-epitope subunit vaccine by examining HIV-1 envelope glycoprotein: An immunoinformatics and viroinformatics approach.

Mishra S, Senathilake K, Kumar N, Patel C, Uddin M, Alqahtani T PLoS One. 2025; 20(2):e0318523.

PMID: 40014623 PMC: 11867397. DOI: 10.1371/journal.pone.0318523.

Impact of Combined Antiretroviral Treatment (cART) on Latent Cytomegalovirus Infection.

Temereanca A, Ene L, Tardei G, Grancea C, Achim C, Ruta S Viruses. 2025; 17(1).

PMID: 39861865 PMC: 11768569. DOI: 10.3390/v17010076.

Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia.

Djojosugito F, Arfianti A, Wisaksana R, Siregar F, Nasronudin N, Rachman B Narra J. 2025; 4(3):e1022.

PMID: 39816057 PMC: 11731923. DOI: 10.52225/narra.v4i3.1022.

New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.

Marra M, Catalano A, Sinicropi M, Ceramella J, Iacopetta D, Salpini R Viruses. 2024; 16(9).

PMID: 39339960 PMC: 11437459. DOI: 10.3390/v16091484.

An Overview of the Recent Advances in Antimicrobial Resistance.

Oliveira M, Antunes W, Mota S, Madureira-Carvalho A, Dinis-Oliveira R, Dias da Silva D Microorganisms. 2024; 12(9).

PMID: 39338594 PMC: 11434382. DOI: 10.3390/microorganisms12091920.

References

Miller M . K65R, TAMs and tenofovir. AIDS Rev. 2004; 6(1):22-33. View

Barber T, Harrison L, Asboe D, Williams I, Kirk S, Gilson R . Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 2012; 67(4):995-1000. DOI: 10.1093/jac/dkr569. View

Este J, Telenti A . HIV entry inhibitors. Lancet. 2007; 370(9581):81-8. DOI: 10.1016/S0140-6736(07)61052-6. View

Wensing A, van de Vijver D, Angarano G, Asjo B, Balotta C, Boeri E . Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005; 192(6):958-66. DOI: 10.1086/432916. View

Hemelaar J, Gouws E, Ghys P, Osmanov S . Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006; 20(16):W13-23. DOI: 10.1097/01.aids.0000247564.73009.bc. View

Doherty K, Nakka P, King B, Rhee S, Holmes S, Shafer R . A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes. BMC Bioinformatics. 2011; 12:477. PMC: 3305535. DOI: 10.1186/1471-2105-12-477. View

Dolling D, Dunn D, Sutherland K, Pillay D, Mbisa J, Parry C . Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 2013; 68(10):2339-43. PMC: 3772741. DOI: 10.1093/jac/dkt199. View

Nasir A, Dimitrijevic M, Romero-Severson E, Leitner T . Large Evolutionary Rate Heterogeneity among and within HIV-1 Subtypes and CRFs. Viruses. 2021; 13(9). PMC: 8473000. DOI: 10.3390/v13091689. View

Stockdale A, Khoo S . Doravirine: its role in HIV treatment. Curr Opin HIV AIDS. 2021; 17(1):4-14. DOI: 10.1097/COH.0000000000000709. View

10.

Mollan K, Daar E, Sax P, Balamane M, Collier A, Fischl M . HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis. 2012; 206(12):1920-30. PMC: 3502379. DOI: 10.1093/infdis/jis613. View

11.

Robertson M, Braunstein S, Hoover D, Li S, Nash D . Timeliness of Human Immunodeficiency Virus Diagnosis and Antiretroviral Treatment Initiation in the Era of Universal Testing and Treatment. J Infect Dis. 2019; 220(4):648-656. DOI: 10.1093/infdis/jiz148. View

12.

van Zyl G, Liu T, Claassen M, Engelbrecht S, de Oliveira T, Preiser W . Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens. PLoS One. 2013; 8(6):e67188. PMC: 3694021. DOI: 10.1371/journal.pone.0067188. View

13.

Lu H, Tang Y . Myths in the laboratory diagnosis of HIV infection. Emerg Microbes Infect. 2019; 8(1):1240-1242. PMC: 6735339. DOI: 10.1080/22221751.2019.1656550. View

14.

Hurt C, Nelson J, Hightow-Weidman L, Miller W . Selecting an HIV Test: A Narrative Review for Clinicians and Researchers. Sex Transm Dis. 2017; 44(12):739-746. PMC: 5718364. DOI: 10.1097/OLQ.0000000000000719. View

15.

Kisic M, Mendieta J, Puertas M, Parera M, Martinez M, Martinez-Picado J . Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region. J Mol Biol. 2008; 382(2):327-41. DOI: 10.1016/j.jmb.2008.07.030. View

16.

Sluis-Cremer N, Tachedjian G . Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 2008; 134(1-2):147-56. PMC: 2745993. DOI: 10.1016/j.virusres.2008.01.002. View

17.

Sun Z, Lan Y, Liang S, Wang J, Ni M, Zhang X . Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18. J Antimicrob Chemother. 2022; 77(4):1119-1124. DOI: 10.1093/jac/dkac016. View

18.

Cooper D, Steigbigel R, Gatell J, Rockstroh J, Katlama C, Yeni P . Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008; 359(4):355-65. DOI: 10.1056/NEJMoa0708978. View

19.

Cohen C, Andrade-Villanueva J, Clotet B, Fourie J, Johnson M, Ruxrungtham K . Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378(9787):229-37. DOI: 10.1016/S0140-6736(11)60983-5. View

20.

Rock A, Lerner J, Badowski M . Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data. HIV AIDS (Auckl). 2020; 12:201-210. PMC: 7293906. DOI: 10.2147/HIV.S184018. View